- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
InnoCare Pharma Ltd (688428)
InnoCare Pharma Ltd stock price live, this page displays SS 688428 stock exchange data. View the 688428 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the InnoCare Pharma Ltd real time stock price chart below.
What Is the InnoCare Pharma Ltd Stock Price Today?
The InnoCare Pharma Ltd stock price today is 29.04.
What Is the Stock Symbol for InnoCare Pharma Ltd?
The stock symbol for InnoCare Pharma Ltd is "688428."
What Stock Exchange Does InnoCare Pharma Ltd Trade On?
InnoCare Pharma Ltd is listed and trades on the Shanghai stock exchange.
Is InnoCare Pharma Ltd a Good Stock to Buy?
Determining whether InnoCare Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 688428 quote. (ISIN: CNE100005P56)
What Is the InnoCare Pharma Ltd Stock Price Today?
The InnoCare Pharma Ltd stock price today is 29.04.
What Is the Stock Symbol for InnoCare Pharma Ltd?
The stock symbol for InnoCare Pharma Ltd is "688428."
What Stock Exchange Does InnoCare Pharma Ltd Trade On?
InnoCare Pharma Ltd is listed and trades on the Shanghai stock exchange.
Is InnoCare Pharma Ltd a Good Stock to Buy?
Determining whether InnoCare Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 688428 quote. (ISIN: CNE100005P56)
29.04
+0.16(+0.55%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.60
30.00
52 wk Range
12.14
33.33
688428 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.6030.00
52 wk Range
12.1433.33
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
688428 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
InnoCare Pharma Ltd Earnings Call Summary for Q2/2026
- H1 2026 revenue jumped 55.5% YoY to RMB 1.137B; net profit reached RMB 240M vs. RMB 36M loss a year earlier, marking return to profitability.
- Orelabrutinib drove most growth; tafasitamab and zurletrectinib contributed in first full commercial year. Cash position stood at RMB 8.4B at June 30.
- Management maintained full-year drug sales growth guidance above 35%, declining to raise outlook until Q3 results reviewed despite strong H1 performance.
- R&D spending rose 10.5% to RMB 497M, supporting 10+ phase III trials across oncology, autoimmune disease, and solid tumor programs through 2027.
- Shares fell 6.96% to $27.54 post-earnings as investors sought guidance increase; management cited need to assess CLL penetration and rural expansion trends.
Last Updated: 2026-08-24, 10:04 a/m
Read Full TranscriptEarnings
Latest Release
Aug 24, 2026
EPS / Forecast
0.08 / --
Revenue / Forecast
608M / --
Compare 688428 to Peers and Sector
Metrics to compare | 688428 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688428PeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.0x | −2.1x | −0.4x | |
PEG Ratio | 0.13 | 0.05 | 0.00 | |
Price/Book | 3.4x | 5.0x | 2.6x | |
Price / LTM Sales | 9.3x | 12.6x | 3.1x | |
Upside (Analyst Target) | - | 40.8% | 48.2% | |
Fair Value Upside | Unlock | −2.4% | 6.5% | Unlock |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the InnoCare Pharma (688428) Stock Price Today?
The InnoCare Pharma stock price today is 29.04 CNY.
What Stock Exchange Does InnoCare Pharma Trade On?
InnoCare Pharma is listed and trades on the Shanghai Stock Exchange.
What Is the Stock Symbol for InnoCare Pharma?
The stock symbol for InnoCare Pharma is "688428."
What Is the InnoCare Pharma Market Cap?
As of today, InnoCare Pharma market cap is 25.76B CNY.
What Is InnoCare Pharma's Earnings Per Share (TTM)?
The InnoCare Pharma EPS (TTM) is 0.51.
When Is the Next InnoCare Pharma Earnings Date?
InnoCare Pharma will release its next earnings report on Nov 16, 2026.
From a Technical Analysis Perspective, Is 688428 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has InnoCare Pharma Stock Split?
InnoCare Pharma has split 0 times.
How Many Employees Does InnoCare Pharma Have?
InnoCare Pharma has 1388 employees.
What is the current trading status of InnoCare Pharma (688428)?
As of Aug 29, 2026, InnoCare Pharma (688428) is trading at a price of 29.04 CNY, with a previous close of 28.88 CNY. The stock has fluctuated within a day range of 28.60 CNY to 30.00 CNY, while its 52-week range spans from 12.14 CNY to 33.33 CNY.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.